YAP1 and colorectal carcinoma: Figure 7G demonstrates that CMD‐BHQ3‐PTL/DOX@RBCm treatment reduced nuclear YAP1 levels and elevated cytoplasmic YAP1 levels in CRC cells, indicating inhibition of YAP1 nuclear translocation.